Tag: Linzagolix

Efficacy and safety of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids: Results from two Phase 3 randomized clinical trials

Posted on by Delphine Renaud

Elizabeth A. Stewart, MD; Hugh S. Taylor, MD; Robert N. Taylor, MD, PhD; Jacques Donnez, PhD, MD; Elke Bestel, MD; Jean-Pierre Gotteland, PhD; Andrew Humberstone, PhD; Elizabeth Garner, MD, MPH

ASRM 2020 Virtual Congress, October 2020

Poster session, Late-breaking abstract – Poster P. 930, page e527

Fertility and Sterility, Volume 114, No. 3, Supplement, September 2020, Poster session, Late-breaking abstract – Poster P. 930, page e527

Linzagolix may address the long-term treatment needs of women with uterine fibroids who have contraindications to hormonal add-back therapy: results from two Phase 3 randomized clinical trials

Posted on by Delphine Renaud

Linda D. Bradley, MD; Erica E. Marsh, MD, MSCI, FACOG; Elizabeth Garner, MD, MPH

ASRM 2020 Virtual Congress, October 2020

Poster session, Late-breaking abstract – Poster P. 931, page e527

Fertility and Sterility, Volume 114, No. 3, Supplement, September 2020, Poster session, Late-breaking abstract – Poster P. 931, page e527

Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial

Posted on by Delphine Renaud

Jacques Donnez, M.D., Ph.D., Hugh S. Taylor, M.D., Ph.D., Robert N. Taylor, M.D., Ph.D., Mark D. Akin, M.D., Tatyana F. Tatarchuk, M.D., Dr. Sc., Krzysztof Wilk, M.D., Jean-Pierre Gotteland, Ph.D., Veronique Lecomte, Pharm.D., Elke Bestel, M.D.

Published online: June 03, 2020

Donnez, Jacques et al. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial. Fertility and Sterility, Volume 114, Issue 1, July 2020, Pages 44-55

Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis

Posted on by Delphine Renaud

Olivier Donnez M.D., Ph.D. , Jacques Donnez M.D., Ph.D.

Published online: June 02, 2020

Donnez, Olivier et al. Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis. Fertility and Sterility, Volume 114, Issue 3, September 2020, Pages 640-645

Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding pattern

Posted on by Delphine Renaud

Pohl O., Marchand L., Bell D., Gotteland JP.

Pohl O, Marchand L, Bell D, Gotteland JP. Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding pattern. Reprod Sci. 2020;27(4):988‐995. doi:10.1007/s43032-020-00172-z

Long Term Treatment of Endometriosis Associated Pain (EAP) With Linzagolix: Efficacy and Safety After 12 Months of Treatment

Posted on by Delphine Renaud

Taylor R., Bestel E., Gotteland JP., Lecomte V., Dubouloz R., Terrill P., Humberstone A., Loumaye E.

ASRM 2019 Scientific Congress & Expo, 12-16 October 2019, Philadelphia, PA

Fertility and Sterility Vol. 112, No. 3, Supplement, September 2019. Abstract on page e323.

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue